5 results
To assess arterial wall inflammation, measured with 18F-FDG PET/CT scan, in patients with intermediate and severe FH phenotype, as well as the change in arterial wall inflammation following PCSK9 inhibition.
Primary:To evaluate the effects of 15 mg E4/3 mg DRSP, of 30 mcg EE/150 mcg LNG, and of 20 mcg EE/3 mg DRSP on hemostasis, endocrine function and lipid and carbohydrate metabolism parameters during 6 treatment cycles.Secondary:To assess the safety…
In the present study, we set out to evaluate arterial wall inflammation in patients at increased CV-risk with statin-associated muscle symptoms (SAMS), precluding effective statin therapy. Following twelve weeks of treatment with PCSK9-Ab, the…
The aim of this pilot study is to further unravel the pathophysiologic mechanism of NS-induced hypercholesterolemia which willfurther guide the treatment of patients with NS.Given the recent insights on PCSK9-ENaC inhibition, our hypothesis is that…
The purpose of this study is to investigate how quickly and to what extent JNJ-64417184 is absorbed and eliminated from the body when it is given together with drugs that reduce the stomach acidity. The study also investigates how safe the new…